GENE ONLINE|News &
Opinion
Blog

2021-06-29| Asia-PacificCOVID-19

Korea to Begin Production of Sputnik Light COVID-19 Vaccine in September

by Tyler Chen
Share To

South Korea has become a global hub for COVID-19 vaccine manufacturing. After Moderna and Novavax made deals with the Korean government in May to produce their vaccines, the country’s pharma companies said they would start producing the Sputnik Light COVID-19 vaccine as early as September.

 

Aim to Produce 30 Million Doses in 2021

Huons Global, the leading company in its vaccine consortium, said on June 28th that they would start manufacturing sample batches of Sputnik V and Light vaccines in August in order to meet the demand from the Russian Direct Investment Fund (RDIF).

The firm once stated in April that it would make 100 million Sputnik V vaccines a month for export purposes, and now it aims to produce 30 million shots by the end of 2021.

The consortium included Korea’s local pharma firms Huons Global, Prestige BioPharma, Humedix, and Boran Pharma. Huons Global commented in May that it would prioritize the local supply of Sputnik V as soon as it is approved in Korea.

 

Another Deal by RDIF

Huons Global isn’t the only one that had a deal with RDIF. 

On April 15, Korea’s Isu Abxis received a technology transfer of Sputnik V from RDIF to produce the vaccine. It said that the pilot production of the vaccine at the facility in Yongin is expected to begin soon.

Isu Abxis is in a vaccine consortium organized by GL Rapha in February. The consortium also included 8 other domestic companies.

 

Still Under Review in Korea

The efficacy of Sputnik Light is 79.4% with a single shot, and according to the real-world data in Argentina, the vaccine has an efficacy of 78.5 to 83.7% among the elderly. As for conditions for storage, Sputnik Light can be transported at the temperature of 2~8 °C, meaning that it doesn’t require cold-chain infrastructures such as vaccines developed by Pfizer and Moderna.

However, currently, Sputnik V and Sputnik Light are not approved or under review in Korea.

Related Article: Korea’s Incheon Airport to Open a Cool Cargo Center to Store COVID-19 Vaccines

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
R&D
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
Saudi Arabia Reveals Grand Ambition to Become a Global Biotech Powerhouse by 2040
2024-01-26
AstraZeneca’s severe asthma drug Tezspire has been granted market authorization in South Korea
2023-12-25
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top